Abstract Dysfunction of the apoptotic pathway in prostate cancer cells confers apoptosis resistance towards various therapies. A novel strategy to overcome resistance is to directly target the apoptotic pathway in cancer cells. Apigenin, an anticancer agent, selectively toxic to cancer cells induces cell cycle arrest and apoptosis through mechanisms which are not fully explored. In the present study we provide novel insight into the mechanisms of apoptosis induction by apigenin. Treatment of androgenrefractory human prostate cancer PC-3 and DU145 cells with apigenin resulted in dose-dependent suppression of XIAP, c-IAP1, c-IAP2 and survivin protein levels. Apigenin treatment resulted in significant decrease in cell viability and apoptosis induction with the increase of cytochrome C in time-dependent manner. These effects of apigenin were accompanied by decrease in Bcl-xL and Bcl-2 and increase in the active form of Bax protein. The apigenin-mediated increase in Bax was due to dissociation of Bax from Ku70 which is essential for apoptotic activity of Bax. Apigenin treatment resulted in the inhibition of class I histone deacetylases and HDAC1 protein expression, thereby increasing the acetylation of Ku70 and the dissociation of Bax resulting in apoptosis of cancer cells. Furthermore, apigenin significantly reduced HDAC1 occupancy at the XIAP promoter, suggesting that histone deacetylation might be critical for XIAP downregulation. These results suggest that apigenin targets inhibitor of apoptosis proteins and Ku70-Bax interaction in the induction of apoptosis in prostate cancer cells and in athymic nude mouse xenograft model endorsing its in vivo efficacy.
Introduction
Prostate cancer is one of the most common malignancies in men and is the major cause of death in American men [1, 2] . Localized prostate cancer is eminently treatable; however, no curative therapy is available once the cancer becomes invasive and metastasizes [3, 4] . While prostate cancer initially responds well to androgen deprivation, this treatment results in the emergence of androgen-independent disease that is resistant to apoptosis [5] . A better understanding of this process could lead to the development of novel therapeutic strategies aimed at reducing mortality and morbidity associated with prostate cancer.
In recent years, many cellular factors involved in apoptosis have been identified and their roles in the apoptotic pathway have been elucidated [6, 7] . Initiation of apoptosis occurs through an extrinsic pathway by the interaction of cell death receptors with their ligands or an intrinsic pathway triggered by release of cytochrome C from mitochondria to the cytosol [6] . Both these pathways converge, which results in the activation of caspase proteolytic reaction. Apoptosis is a complex process regulated by several molecules that function as either promoters, including Bax, Bak, and caspases, or inhibitors of the cell death process such as Bcl-2, Bcl-xL, and the IAP family of proteins [7] . Over-expression of IAP proteins, including X-linked inhibitor of apoptosis (XIAP), IAP-1, IAP-2 and survivin, has been demonstrated in clinically derived prostate tumor specimens as well as patient derived cancer cell lines [8] [9] [10] . Several members of the IAP family have been shown to bind and directly suppress the activity of certain caspases, thereby suppressing apoptosis [11] . High XIAP expression has been shown to be a strong and independent predictor of prostate cancer recurrence and poor clinical outcome [12] . Similarly, increased survivin has been detected in human prostate cancer and its degree of expression correlates with tumor progression and increased invasiveness [13] .
Another mechanism of apoptosis induction is activation of pro-apoptotic protein Bax [14] . In normal cells, Bax interaction with the C-terminus of the Ku70 protein has been shown to suppress apoptosis by sequestering it from the mitochondria [15, 16] . Ku70 is post-transcriptionally regulated by acetylation of the lysine residues in the C-terminal linker domain, resulting in release of Bax. Acetylation of Ku70 is regulated by histone acetyltransferase and histone deacetylase, the two opposing group of enzymes primarily involve in chromatin remodeling [17, 18] . Recent reports indicate a positive relationship between Ku70 and cancer progression and resistance to various therapies, highlighting Ku70-Bax interaction as an important therapeutic target [19] .
Bioactive food components continue to gain attention for chemoprevention and/or therapy of prostate cancer [20] [21] [22] . Apigenin (4,5,7-trihydroxyflavone) is one such plant flavone under active investigation as an anticancer agent for prostate cancer as well as other type of malignancy, including cancers of colon, skin, lung and breast [23] [24] [25] [26] . Mechanistic studies have suggested that apigenin exerts chemoprotective effects by blocking multiple signal transduction pathways such as NF-rB, IGF-I axis, PI3K-Akt, HIF-1a and b-catenin in various experimental models of prostate cancer [27] [28] [29] [30] [31] . Studies have shown that apigenin-induced prostate cancer cell death is initiated by generation of reactive oxygen species and p53 activation [32] . Apigenin has been shown to modulate MAPK, PI3K-Akt and loss of cyclin D1 associated with dephosphorylation of the tumor suppressor, retinoblastoma [33] . Apigenin inhibits focal adhesion kinase and Src kinase, resulting in decreased cell motility and cytoskeleton remodeling in invasive prostate cancer cells [34] . We have previously demonstrated that apigenin treatment of prostate cancer cells causes cell growth inhibition and arrest in the G0/G1 phase of the cell cycle, a function that was associated with increased levels of p21/waf1 and Bax proteins [27] . Additionally, we found evidence for the loss of Bcl-2 expression and increased multi-caspase activity, resulting in apoptosis [35] . More recently we have shown that apigenin inhibits class I HDACs in prostate cancer cells [36] . Based on these findings we sought to determine the role of IAP family proteins and Ku70-Bax interaction in apigenininduced apoptosis using androgen-refractory human prostate cancer PC-3 and DU145 cells and PC-3 xenograft in athymic nude mice.
Materials and methods

Cell culture and reagents
Androgen refractory human prostate cancer cell lines PC-3 and DU145 were purchased from American Type Culture Collection. These cancer cell lines were cultured as monolayers in RPMI 1640 supplemented with 5 % heat-inactivated fetal bovine serum and 100 lg/ml streptomycin (Cellgro, VA) and maintained in an incubator with a humidified atmosphere of 95 % air and 5 % CO 2 at 37°C. Apigenin (A.G. Scientific, Inc., CA), embelin (Biomol International, PA), trichostatin A (TSA) (Sigma-Aldrich, MO), pan-caspase Inhibitor; Z-VAD-FMK, caspase-9 Inhibitor; Z-LEHD-FMK, caspase-3 Inhibitor; Z-DEVD-FMK purchased from BioVision, CA were added to the complete cell culture medium (maximum concentration of DMSO, 0.1 % (v/v) in medium) before addition to subconfluent cells (60-70 % confluent). Cells treated only with DMSO served as a vehicle control. The following antibodies anti-XIAP (cat# 2045), anti-c-IAP1 (cat# 4952), anti-c-IAP2 (cat# 3130), anti-survivin (cat# 2808) anti-Bcl-XL (cat# 2762), anti-Bad (cat# 9292), anti-cleaved caspase-3 (cat# 9661), anti-caspase-9 (cat# 9501), anticleaved PARP (cat# 9544) were obtained from Cell Signaling, Beverly, MA whereas anti-BCl2 (cat# sc7382), anti-Bax (cat# sc493), anti-p21/waf1 (cat# sc817), anti-CBP (cat# sc583), anti-HDAC1 (cat# sc7872), anti-cytochrome-C (cat# sc13560) were procured from Santa Cruz Biotechnology, Santa Cruz, CA. Anti-Ku70 (H-308) (cat# sc9033) was a kind gift from Dr. Shigemi Matsuyama, Department of Pharmacology, Case Western Reserve University, Cleveland, OH.
Cell viability assay
The effect of apigenin on cell proliferation was determined by MTT [3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazoliumbromide] assay and growth inhibition was assessed as the percent viability where vehicle-treated cells were taken as 100 % viable as previously described [36] .
HDAC activity assay
Histone deacetylases (HDACs) activity was measured in PC-3 whole cell lysate after apigenin treatment at various times, according to the vendor's protocol using colorimetric HDAC activity assay kit (cat # #K331-100) from BioVision, CA.
Immunoprecipitation PC-3 cells, after treatment with apigenin and TSA for 24 h, were lysed in buffer containing 50 mM Hepes pH 7.4, 60 mM KCl, 15 mM NaCl, 0.65 mM spermidine, 0.34 M saccharose, 2 mM EDTA, 0.5 mM EGTA, 0.5 mM DTT, 0.05 % Triton-X and cocktail protease inhibitors (Roche USA, Madison, WI). Cells were incubated on ice for 15 min and then sonicated at 250 J. Preclearing of proteins were performed using 20 ll of AG-Plus agarose beads (Santa Cruz) with 200 lg of protein extracts. Immunoprecipiation was performed using 200 lg of protein extracts incubated for 6 h with 5 lg Ku70 antibody and AG-Plus Agarose. Further three times washing of this complex was performed with the same lysis buffer by spinning at 3,000 rpm for 10 min. Western blot of pelleted complex was performed and transferred nitrocellulose membrane was probed with acetylated lysine and Bax antibody to show the association between the Ku70 and Bax and the levels of acetylated lysine after apigenin treatment. Tumor xenograft study
The animal experiment was conducted in accordance with the guidelines established by the University's Animal Research Committee and with the NIH Guidelines for the Care and Use of Laboratory Animals. Approximately 1 million PC-3 cells suspended in 0.05 ml medium and mixed with 0.05 ml Matrigel were subcutaneously injected in the left and right flank of each mouse to initiate tumor growth. After implantation, the animals were kept under supervision for growth of tumor. Two weeks after cell inoculation, animals were divided into three equal groups of six mice each. Apigenin (10 mg) was suspended in 1 ml vehicle material (0.5 % methyl cellulose and 0.025 % Tween 20) by sonication for 30 s at 4°C and further diluted for appropriate concentration. Apigenin, 20 and 50 lg/mouse/day was administered by gavage in 0.2 ml of a vehicle, daily for 8 weeks throughout the study. These doses are comparable to the daily consumption of flavonoid in humans as reported in previously published studies [23] [24] [25] [26] 37] . The first group received only 0.2 ml vehicle material by gavage daily and served as a control group. The second and third groups of animals received 20 and 50 lg/ mouse/day doses of apigenin in vehicle for 8 weeks, respectively.
Statistical analysis
Changes in tumor volume and body weight during the course of the experiments were visualized by scatter plot. Differences in tumor volume (mm 3 ) and body weight at the termination of the experiment among various groups were examined using analysis of variance (ANOVA) followed by Tukey's multiple comparison procedure. The statistical significance of differences between control and treatment group was determined by simple ANOVA followed by multiple comparison tests. All tests were two-tailed and P values \0.05 were considered to be statistically significant.
Results
Initially, we determined dose-response and time course kinetic effect of apigenin on cell viability and apoptosis induction using androgen-refractory human prostate cancer PC-3 and DU145 cells. Apigenin treatment reduced viability of PC-3 and DU145 cells in a dose-dependent manner (data not shown). Treatment of PC-3 cells with 5-40 lM apigenin caused 18-51 % and DU145 cells resulted in 8-58 % decrease in cell viability. Both the cell lines were sensitive to apigenin-mediated reduction in cell survival. Next we determine the apoptotic effects of apigenin which may be through activation of a cascade of caspases. Because PARP-specific proteolytic cleavage by caspases is considered to be characteristic of apoptosis, the cleavage of caspase 9 and caspase 3 were evaluated. Treatment of PC-3 and DU145 cells with 20 lM apigenin caused activation of caspase 9 in time-dependent manner as indicated by increase in cleaved product of caspase 9. Activation of caspase 3 was detected after apigenin treatment as a double band representing the p19 proteolytic fragment and the active subunit p17, respectively. Similar results were observed in PARP cleavage, further indicating the specificity of the apoptotic effect of apigenin by caspase activation in prostate cancer cells (Fig. 1a) .
To confirm the mechanism responsible for apigeninmediated apoptosis, prostate cancer cells were pretreated with broad spectrum caspase inhibitor (z-VAD-fmk), a caspase 9 specific inhibitor (z-LEHD-fmk) and a caspase 3 specific inhibitor (z-DEVD-fmk). Cell viability measurement was performed after 24 h incubation with apigenin with or without 1 h pretreatment with these caspase inhibitors at 150 lM dose. Pre-treatment of cells with all three caspase inhibitors significantly reduced the ability of apigenin to induce cell death in PC-3 and DU145 cells (Fig. 1b) . The caspase inhibitor alone did not cause any significant change in cell viability (data not shown).
Members of the IAP family of protein, including XIAP, survivin, c-IAP1 and c-IAP2 have emerged as critical regulators of apoptotic cell death by various stimuli [8] [9] [10] [11] . We sought to determine the possible role of these proteins in regulation of apigenin-induced apoptosis. As shown in Fig. 2 , treatment of PC-3 and DU145 cells with apigenin resulted in a dose-dependent downregulation of XIAP protein expression. The effect of apigenin treatment on survivin was relatively less pronounced compared to XIAP. Nonetheless, apigenin-mediated down-regulation of survivin protein was clearly discernable after treatment of PC-3 and DU145 cells with 20 and 40 lM apigenin for 24 h. Moreover, expression of c-IAP1 and c-IAP2 protein was markedly reduced in both PC-3 and DU145 cells after apigenin treatment (Fig. 2) .
The cleavage of caspase 9/3 by apigenin suggests that its apoptotic effect involves the mitochondrial apoptotic pathway. As shown in Fig. 3a , treatment of PC-3 cells with 20 lM apigenin was followed by an obvious increase in cytochrome C in time-dependent manner. Specifically the upregulation of cytochrome C by apigenin was increased at 3 h and sustained until 24 h. Since Bcl-2 family protein influences cellular apoptosis via regulation of the cytochrome C release, which then mediates caspase activation, the effects of apigenin on the protein expression of antiapoptotic Bcl-2, Bcl-xL and pro-apoptotic protein Bad and Bax was evaluated. Treatment of PC-3 cells with 20 lM apigenin from 3 to 24 h inhibited protein expression of Bcl-2 and Bcl-xL in a time-dependent manner. Furthermore, apigenin treatment resulted in increased protein expression of Bad and Bax in a time-dependent manner. Increased Bax expression was observed as early as 3 h of apigenin treatment with further increase up to 24 h. A simultaneous decrease in Bcl-2 tilted the Bax/Bcl-2 ratio in favor of apoptosis (Fig. 3b) . Since Bax is mutated in DU145 cells, we performed further studies on PC-3 cells. Taken together, these data suggest that cytochrome C activation and Bcl-2 family regulation in response to apigenin play a role in induction of apoptosis.
To understand the mechanism of apigenin-mediated apoptosis of prostate cancer cells we focused our attention on histone modifying enzymes. Studies have demonstrated that histone deacetylase inhibitor trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA) induce apoptosis in cancer cells by downregulation of Bcl-2 and XIAP [38] . We evaluated HDAC activity and protein expression after apigenin treatment. As shown in Fig. 4a , exposure of PC-3 cells to 20 lM apigenin resulted in significantly decreased total class I HDAC activity. Apigenin-mediated decrease in HDAC activity was initiated at 3 h and sustained through 24 h of exposure. A significant decrease in HDAC1 protein expression was observed after apigenin treatment to these cells (Fig. 4a) . To determine the relationship between HDAC1 and XIAP, in the next experiment PC-3 cells were used to knockdown HDAC1 by siRNA interference, treated with 20 lM apigenin and 20 lM embelin, a known inhibitor of XIAP for 24 h. Knockdown of HDAC1 resulted in significant decrease in XIAP protein expression. Treatment of cells with apigenin resulted in marked decrease in HDAC1 and XIAP protein, whereas embelin treatment resulted in downregulation of XIAP protein. This correlated with simultaneously reduced viability of PC-3 cells, which was highest after apigenin treatment. No significant changes in the CBP protein level was noted after these treatments (Fig. 4b, c) .
Based on the ability of apigenin to inhibit HDAC1, we anticipated that downregulation of HDAC1 is critical for XIAP suppression. To further confirm our findings, we examined the recruitment of CBP/p300 and HDAC1 to the XIAP promoter after apigenin treatment. As shown in Fig. 4d , neither CBP/p300 was associated with XIAP promoter; however, apigenin significantly reduced HDAC1 occupancy at the XIAP promoter, suggesting that histone decaetylation may be critical for XIAP downregulation.
Our earlier experiments have shown that apigenin inhibits class I HDAC activity and expression in prostate cancer cells [36] . This might affect the dynamic balance between deacetylation and acetylation processes affecting gene expression. Since Ku70-Bax interaction regulates Bax-mediated mitochondrial apoptosis [15, 16] , we studied the effect of apigenin on Bax and Ku70 expression. As shown in Fig. 5a , treatment of PC-3 cells with apigenin resulted in dose-dependent increase in Bax expression, whereas a modest increase was observed in Ku70 protein expression. Studies have shown that HDAC inhibitors increase acetylation of Ku70, facilitating Bax release from Ku70 and in turn inducing apoptosis [17] . Next we immunoprecipitated Ku70, followed by probing of the immunocomplex with an antibody against acetylated lysine. As shown in Fig. 5b , treatment with 20 lM apigenin resulted in increased acetylation of Ku70, and its interaction with Bax was decreased after apigenin treatment. Similar results were noted after treatment of cells with 80 nM trichostatin A, a HDAC inhibitor, which also resulted in increased Ku70 acetylation and its decreased association with Bax, initiating Bax-mediated apoptosis (Fig. 5c) .
Our previous experiments have demonstrated the effectiveness of apigenin in inducing apoptosis in prostate cancer cells by downregulation of the IAP family of proteins. We extended these studies to determine whether these events occur in vivo using a PC-3 tumor xenograft model. We designed a protocol that simulates a therapeutic regimen, wherein apigenin was provided at 20 and 50 lg/ mouse/day through gavage after 2 weeks of cell inoculation and continued for 8 weeks. In this experimental protocol, intake of apigenin inhibited the growth of tumor xenograft at both test doses. As shown in Fig. 6a and b, tumor volume was inhibited by 32.5 and 51.3 % (P \ 0.001) and the wet weight of tumor was decreased by 33.3 and 55.1 % (P \ 0.001), respectively, at the termination of the experiment. There were no adverse effects of apigenin treatment on animal health, food intake or body weight (data not shown). The average daily intake of food did not differ between the control and treated groups. Moreover, body weight was not significantly different throughout the duration of the study, suggesting that apigenin was essentially non-toxic at the dietary concentrations used in the study. At the termination of the study, xenografts were examined for the extent of tumor cell apoptosis. Compared to the untreated controls, induction of apoptosis was significantly increased in tumor xenografts in the same mice (P \ 0.001) (Fig. 6b) . We also measured the protein expression of XIAP and survivin as an effect of apigenin feeding. As shown in Fig. 6c , oral intake of apigenin at doses of 20 and 50 lg/mouse/day resulted in marked reduction in the protein expression of XIAP and survivin in PC-3 tumor xenografts. A dose-dependent decrease in HDAC1 expression, increase in Bax and PARP cleavage was observed in apigenin-administered mice.
Discussion
The present study reveals for the first time that apigenin treatment causes inhibition of XIAP, survivin, c-IAP1 and c-IAP2 in androgen-refractory PC-3 and DU145 prostate cancer cells. Furthermore, apigenin treatment led to decreased HDAC1, causing increased acetylation and disruption of Ku70-Bax interaction, thereby releasing Bax in the cytosol. Apigenin-mediated increase in Bax levels promotes apoptosis in prostate cancer cells.
The inhibitor of apoptosis protein is a family of structurally homologous cell survival molecules characterized by the presence of one to three baculoviral (BIR) IAP repeats in the BIR domain [39, 40] . The human IAP family consists of eight protein including NAIP (BIRC1), cIAP-1 (BIRC2), c-IAP2 (BIRC3), XIAP (BIRC4), survivin (BIRC5), Apollon/Bruce (BIRC6), ML-IAP (BIRC7 or livin) and ILP-2 (BIRC8), respectively. IAPs have been shown to protect cells from a wide range of apoptotic triggers, including FAS ligation, Bax, activated caspases, cytochrome C, TNFa as well as from stress including therapeutic agents, infection and radiation [40] . Studies demonstrate poor correlation between XIAP, c-IAP1, c-IAP2 protein levels with mRNA levels, consistent with emerging knowledge that expression of many IAPs is regulated predominantly at the level of protein stability [8] [9] [10] 41] . Previous studies have demonstrated that androgenindependent prostate cancer cells have elevated levels of a range of anti-apoptotic proteins, including IAPs and Bcl-2 family members [8] [9] [10] , which forms the rationale for targeting these proteins. Current efforts are focused on the development of new therapeutic agents derived from natural sources. Of the eight IAP protein members identified to date, XIAP is the best characterized and most potent inhibitor of apoptosis [8] [9] [10] 12] . Transient transfection of prostate cancer cells with XIAP targeting siRNA produced a prominent downregulation of XIAP that resulted in apoptosis and significantly increased sensitivity to chemotherapeutic drugs [42] . Higher XIAP expression has been demonstrated in high-grade PIN lesions, and its aberrant expression correlates with prostate cancer progression and poor prognosis [12] . The XIAP protein is structurally characterized by 3 BIR domains (BIR1, BIR2, and BIR3) and a ring-finger domain. Although BIR2 and BIR3 domains are necessary for XIAP to bind and inhibit caspase, the BIR1 of XIAP has been shown to interact with TAK1 binding protein, (TAB 1), an interaction that is essential for the recruitment of TAK1 and subsequent activation of NF-rB [43] . Apigenin-induced cell death is due to downregulation of XIAP and release of caspase 9 followed by activation of caspase 3 leads to apoptosis. Cells exposed to apigenin prior to treatment with caspase9/ 3 inhibitor, and general caspase inhibitor exhibit reduced cell death. These data indicate that apigenin-induced cell death is mediated by caspase activity. Another important role for the IAPs is in their regulation of NF-rB. Activation of NF-rB in tumor cells leads to increased transcription of the anti-apoptotic and pro-survival genes in these cells [39, 40] . Our previous studies have shown that apigenin-mediated apoptosis occurs through inhibition of NF-rB activation, which may occur through inhibition of IAP levels [27] . It would be interesting to explore the precise involvement of NF-rB and IAPs in apigenin-induced apoptosis of prostate cancer cells.
Survivin is another important member of the IAP family, implicated in control of apoptosis [8, 9] . Functional studies have demonstrated that suppression of survivin causes spindle defects and promotes apoptosis [44] . Survivin is strongly expressed in embryonic and fetal organs, but is undetectable in most terminally differentiated tissues. Survivin is over-expressed in most common forms of human cancer including prostate cancer [10, 13] . Survivin has been associated with established features of biologically aggressive prostate cancer, such as higher Gleason score and metastasis to regional lymph nodes, and consequently it is considered as a promising target for cancer therapy [13] . Our present study demonstrates that apigenininduced apoptosis is mediated by downregulation of survivin both in cell culture and in an in vivo model of prostate cancer. Other family members of IAPs, including c-IAP1 and c-IAP2, are often simultaneously higher in clinical specimens and patient derived prostate cancer cell lines [8] [9] [10] 41] . Expression of c-IAP1 and c-IAP2 is cell cycle dependent, peaking at the G2/M phase of the cell cycle and contributing to survival during mitotic arrest. An integrative oncogenomic approach classifies c-IAP1 and c-IAP2 as possessing oncogenic properties. Over-expression of c-IAP1 in DU145 cells has been shown to trigger polyploidy. Knockdown of c-IAP1 protein increases spontaneous apoptosis in prostate cancer cells [45] . In the present study, apigenin treatment to PC-3 and DU145 cells exhibit inhibition of c-IAP1 protein during apoptosis. Studies have demonstrated upegulation of c-IAP1 and c-IAP2 levels in tumor cells after knockdown of XIAP by siRNA [46] . This may be a reason for failure of targeting individual IAP in cancer and advisable that simultaneous knockdown of all over-expressed IAPs may increase basal apoptosis levels. Our study demonstrates that apigenin has the potential to simultaneously target all IAPs including XIAP, survivin, c-IAP1 and c-IAP2, which are overexpressed in androgen-refractory prostate cancer cells. A similar study has demonstrated the importance of targeting multiple IAPs in enhancing the sensitivity of prostate cancer cells to apoptosis-inducing agents [46] . It will be worthwhile to study the effect of apigenin in sensitizing highly aggressive prostate cancer cells to chemotherapeutic agents. Apoptosis is a key tumor suppressor mechanism and can be initiated by activation of the pro-apoptotic factor Bax. Overall Bax activation seems to play a central role in mitochondria-dependent apoptosis [14] [15] [16] . The BH3-only proteins, including Bad, Bim/Bod, Bmf, Bik/Npk, BNIP3/ NIX, BIK, NIP3, Noxa and Puma are immediate upstream triggers for Bax activation, either directly or indirectly by sequestration of anti-apoptotic protein Bcl-2 and Bcl-xL proteins [14] . In addition, Bax activation is regulated by p53 via transcriptional dependent and/or independent mechanism [6] . We showed that apigenin treatment significantly increased apoptotic effects in human prostate cancer cells, which do not possess wild-type p53, suggesting that apigenin-mediated increase in Bax is p53 independent. Further studies are needed to identify the mechanism of Bax increase in prostate cancer cells after apigenin treatment.
Recently it has been reported that changes in histone deacetylase (HDAC) expression in prostate cancer cells may be involved in mechanisms of abnormal cellular proliferation and may operate through chromatin-independent pathways [47] . Class I HDAC (HDAC1, 2, 3 and 8) are over-expressed in prostate cancer [6, 48] . HDAC1 and HDAC3 are highly expressed in prostate cancer and HDAC2 has been shown to be associated with shorter PSA relapse time [48] . HDAC1 plays a critical role in the transition of prostate cancer cells from androgen dependence to androgen independence [49] . Studies have shown that treatment of prostate cancer cells with HDAC inhibitors results in XIAP inhibition and increased apoptosis [42] . Our studies demonstrate that apigenin treatment of prostate cancer cells causes a rapid decrease in HDAC1 and loss of HDAC1 recruitment leads to histone deacetylation at the XIAP promoter. Additional studies of the decrease of HDAC1 and its effect on IAPs by apigenin are needed.
Histone modifying enzymes, histone deacetylases and histone acetyltransferase, the two opposing group of enzymes affect gene transcription through acetylation/ deacetylation of histone and non-histone proteins, including p53, HSP90, Ku70, RelA/p65 and STATs, which play important roles in cell proliferation, survival and apoptosis [50] . Ku70, a DNA repair protein, has recently been shown to suppress apoptosis by sequestering Bax from mitochondria. Several studies have demonstrated the involvement of Ku70 and Bax inactivation in various human cancers, genotoxic and chemotherapeutic resistance [19] . Another study has shown that Ku70 is a target of class I/III HDAC and its deacetylation suppresses release of Bax from K70/80 complex in the nucleus and in turn results in Bax-induced apoptosis [16] . Acetylation of Ku70 by acetyltransferase such as CBP/p300 and PCAF in the C-terminal domain of Ku70 releases Bax from the Ku70/Ku80 complex [15, 16] . In our studies, apigenin-mediated decrease in HDAC1 shifts the acetylation/deacetylation equilibrium in favor of acetylation, causing increased acetylation of the lysine residues of Ku70, thereby releasing Bax from the complex and inducing apoptosis of prostate cancer cells (Fig. 5c ). It would be interesting to determine the involvement of p53, RelA/p65 acetylation in prostate cancer cells by apigenin and their role in cell death.
In our cell culture studies, we observed induction of apoptosis, as well as impairment in cell survival, by exposure of prostate cancer cells to apigenin at 20 and 40 lM concentrations. Although these findings provide mechanistic insights, demonstration that these effects are also operative in vivo is required to establish a potential for clinical development. Our in vivo studies using 20 and 50 lg/day apigenin administration to mice with prostate cancer xenografts confirmed that apigenin intake significantly inhibited tumor growth, without any apparent signs of toxicity. Consistent with the findings in cell culture, apigenin intake resulted in downregulation of XIAP, survivin, HDAC1 protein expression, and increase in the levels of Bax favoring apoptosis, compared with control group. The dose of apigenin which is effective in vivo corresponds to an intake of 3.4 and 8.5 mg/day by an adult healthy 70 kg individual. These results indicate that apigenin is bio-available at these concentrations and has a therapeutic effect [31] .
In summary, some critical conclusions drawn from the study are that apigenin has the ability to target the IAP family of proteins in prostate cancer cells and their inhibition renders cancer cells susceptible to apoptotic cell death. Furthermore, the IAP family of proteins may serve as surrogate biomarkers to assess apigenin response in clinical investigations. In conclusion, apigenin alone or in combination with other therapeutic modalities such as radiation and chemotherapy appears to have potentially beneficial activity in the management of highly aggressive prostate cancer.
